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Hypomorphic	mutations	in	DNA	ligase	IV	(LIG4)	cause	a	human	syndrome	of	immunodeficiency,	radio-
sensitivity,	and	growth	retardation	due	to	defective	DNA	repair	by	the	nonhomologous	end-joining	(NHEJ)	
pathway.	Lig4-null	mice	are	embryonic	lethal,	and	better	mouse	models	are	needed	to	study	human	LigIV	
syndrome.	We	recently	identified	a	viable	mouse	strain	with	a	Y288C	hypomorphic	mutation	in	the	Lig4	
gene.	Lig4Y288C	mice	exhibit	a	greater	than	10-fold	reduction	of	LigIV	activity	in	vivo	and	recapitulate	the	
immunodeficiency	and	growth	retardation	seen	in	human	patients.	Here,	we	have	demonstrated	that	the	
Lig4Y288C	mutation	leads	to	multiple	defects	in	lymphocyte	development	and	function,	including	impaired	
V(D)J	recombination,	peripheral	lymphocyte	survival	and	proliferation,	and	B	cell	class	switch	recombina-
tion.	We	also	highlight	a	high	incidence	of	thymic	tumors	in	the	Lig4Y288C	mice,	suggesting	that	wild-type	LigIV	
protects	against	malignant	transformation.	These	findings	provide	explanations	for	the	complex	lymphoid	
phenotype	of	human	LigIV	syndrome.
Introduction
Nonhomologous end joining (NHEJ) is one of the main pathways 
for repair of DNA double-strand breaks (DSBs) (1). The pathway 
comprises 6 core components: Ku70, Ku80, DNA-dependent pro-
tein kinase catalytic subunit (DNA-PKcs), XRCC4, DNA ligase IV 
(LigIV) (1), and the recently discovered XRCC4-like factor (XLF) 
(2, 3). The end-joining process starts with the binding of Ku70/
Ku80 heterodimers to the DNA ends, followed by DNA-PKcs and 
other enzymes involved in end processing. LigIV is subsequently 
recruited to the DNA ends in complex with XRCC4 and, together 
with XLF, catalyzes the final end-joining reaction.
At least 10 hypomorphic mutations in the LIG4 gene have been iden-
tified in the human population, and in homozygous or compound 
heterozygous states, they cause a condition known as LigIV syndrome 
(4–11) (Supplemental Table 1; supplemental material available online 
with this article; doi:10.1172/JCI32743DS1). The clinical presenta-
tion of the syndrome is complex and heterogeneous and may include 
radiosensitivity, varying degrees of lymphopenia, growth retardation, 
and microcephaly (4–12). At the molecular level, all the features of the 
LigIV syndrome are thought to arise from impaired DNA DSB repair, 
and the complexity of the syndrome highlights the functions of the 
NHEJ pathway in many physiological processes.
The embryonic lethality of the Lig4-null mouse strains (13, 14) 
limits their utility as models of LigIV syndrome. Other NHEJ-defi-
cient strains — Ku70, Ku80, and DNA-PKcs–null mice — are viable 
and share some of the phenotypic features of LigIV syndrome 
(15–19). However, the essential nature of Lig4 but not Ku70, Ku80, 
or DNA-PKcs attests to differing impact of these genes. Further, at 
the molecular level, the impact of these alleles is not equivalent to 
that of Lig4-null or -mutant alleles. For example, the functions of 
Ku70, Ku80, and DNA-PKcs are not limited to DNA DSB repair, 
and all 3 proteins are also required for normal telomere mainte-
nance (20, 21). Additionally, residual DSB rejoining can occur in 
the absence of DNA-PKcs and, to a lesser extent Ku, in G0 phase 
cells despite being LigIV dependent (19, 22). Furthermore, and 
possibly underlying the differences in DSB rejoining, the “acces-
sibility” of DNA ends to alternative repair pathways is believed to 
differ in cells deficient in different NHEJ components (23, 24). The 
differences between Ku and LigIV deficiencies are further high-
lighted by the surprising observation that a loss of Ku can partly 
rescue the lethality of the Lig4-null strain (23). Thus, at least at 
the molecular level, some features of the previously characterized 
NHEJ-null mouse strains are distinct from those of the Lig4-null 
mouse and the human LigIV syndrome, suggesting that a LigIV-
mutant mouse strain is a more appropriate model for human 
LigIV syndrome than the existing NHEJ-deficient lines.
DNA DSBs can form as the result of random DNA damage and 
also during programmed DNA rearrangement events, namely 
V(D)J recombination and Ig class switching (25, 26). The pheno-
typic effects of impaired V(D)J rearrangement are widely known 
and account for a complete arrest in lymphocyte development in 
Lig4-null (13) and other NHEJ-null mice (15–19) and most likely 
Conflict	of	interest: The authors have declared that no conflict of interest exists.
Nonstandard	abbreviations	used: CGG, chicken γ globulin; DNA-PKcs, DNA-
dependent protein kinase catalytic subunit; DSB, DNA double-strand break; ENU, 
ethylnitrosourea; HEL, hen egg lysozyme; IgH, Ig heavy-chain locus; LigIV, DNA ligase 
IV; MEF, mouse embryonic fibroblast; NHEJ, nonhomologous end joining; NP,  
4-hydroxy-3-nitrophenylacetyl aminoethylcarboxymethyl; TC, Tricolor; VHL, variable 
heavy light; XLF, XRCC4-like factor.
Citation	for	this	article: J. Clin. Invest. 119:1696–1705 (2009). doi:10.1172/JCI32743.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 6   June 2009 1697
also for the lymphopenia in LigIV syndrome (4, 6–8). The phe-
notypic effects of the impaired repair of nonprogrammed DNA 
damage are more diverse and difficult to study. They include the 
increased apoptosis in the developing brain causing the lethality 
of the Lig4-null mice (13, 14), the progressive decline in hemato-
poietic stem cells in the Lig4Y288C strain (27), and the impaired ex 
vivo lymphocyte proliferation (28, 29) and increased accumulation 
of chromosome breaks in the lymphocytes in LigIV syndrome (4). 
Although such defects in cell survival and proliferation are likely 
to have an impact on the immune system, their contribution to the 
immunodeficiency of the LigIV syndrome remains unknown.
Another physiological source of DNA DSBs is immunoglobulin 
class switching (30, 31), which is a somatic rearrangement of the 
Ig heavy-chain (IgH) locus, occurring in B cells during the immune 
response and resulting in a switch in the antibody isotype. The 
DNA rearrangement is initiated by activation-induced deaminase, 
and the uracil lesions introduced by activation-induced deaminase 
into the switch-region DNA are processed to DSBs. Overwhelm-
ing evidence indicates that NHEJ has a role in the rejoining of 
the breaks, including evidence from the earlier studies of Ku- and 
DNA-PKcs–null mice (28, 29, 32–34) and the recent work on the 
conditional XRCC4 knockout, Lig4–/–p53–/–, and XLF-null mouse 
Figure 1
Partial arrest in lymphocyte development in Lig4Y288C 
strain. (A) Flow cytometry profiles of the thymus of WT, 
Rag1–/–, and Lig4Y288C mice stained for CD4, CD8, CD44, 
and CD25 and gated on total thymocytes (upper panels) 
or CD4–CD8– double-negative thymocytes (lower panels). 
Numbers represent the percentages of cells in the plot that 
fall within the different regions, corresponding to different 
stages of thymocyte differentiation. (B) Absolute number 
of CD4–CD8– double-negative (DN), CD4+CD8+ double-
positive (DP), and CD4 and CD8 single-positive cells in 
the thymus of WT, Rag1–/–, and Lig4Y288C mice. Bars rep-
resent mean ± 95% CI; n ≥ 6. (C) Flow cytometry of the 
bone marrow of WT, Rag1–/–, and Lig4Y288C mice stained 
for B220, IgM, IgD (upper panels), or for B220 and CD43 
(lower panels) and gated on B220+ cells or total lympho-
cytes, respectively. Numbers represent the percentages 
of cells in the plot that fall within the different regions, cor-
responding to different stages of B cell differentiation. (D) 
Absolute numbers of B220+CD43+ pro–B, B220+CD25+ 
pre–B, and B220+IgM+IgD– immature B cells in the bone 
marrow of WT, Rag1–/–, and Lig4Y288C (1 tibia and femur). 
Bars represent mean ± 95% CI; n ≥ 5.
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strains, and a Lig4-null CH12F3 B cell lymphoma line (35–38). The 
recent studies indicate that, although NHEJ is involved, an alterna-
tive microhomology-mediated repair pathway can to some extent 
compensate, with residual levels of switching in the NHEJ-null B 
cells being as high as 25%–50% of the WT level. The alternative 
pathway was also implicated in class switching in the LigIV syn-
drome patients, based on the analysis of the structures of switch 
junctions (39). However, the quantitative impact of hypomorphic 
LigIV mutations on switching remains unknown.
Aberrant repair of DNA DSBs arising through any of the mecha-
nisms described above could lead to chromosomal translocations, 
transformations, and cancer. Previous studies in mice indicate that 
the loss of NHEJ on its own results in only a mild predisposition to 
cancer in some strains (40–42). However, a combined loss of NHEJ 
and DNA damage cell-cycle checkpoints leads to a dramatic increase 
in lymphoid malignancies, as seen in the NHEJ-deficient p53–/– 
mouse strains (43–45). In these mice, the tumors arise 
due to aberrant resolution of DNA DSBs during V(D)J 
recombination and carry translocations involving IgH 
and c-myc loci. Lymphomas were also reported in some 
LigIV syndrome patients (5, 8, 9, 11), although their 
frequency and the mechanism of carcinogenesis are 
difficult to ascertain. They may have arisen as a direct 
result of impaired DNA repair and genomic instability 
or as a secondary effect of immunodeficiency (8, 9). 
Furthermore, there may be significant bias in our esti-
mates of lymphoma predisposition in this syndrome 
as, on the one hand, patients with severe forms of the 
disease commonly undergo bone marrow transplanta-
tion (7, 8, 10), while on the other hand, some patients 
with milder forms of the condition are diagnosed with 
LigIV syndrome only following adverse responses to 
radio- or chemotherapy (5, 11).
We recently identified an ethylnitrosourea-induced 
(ENU-induced) hypomorphic mutation in the Lig4 
gene in a mouse strain that displays the common fea-
tures of the LigIV syndrome, including lymphopenia 
and growth retardation (27). The in vivo LigIV activ-
ity in the Lig4Y288C mice is reduced over 10-fold, simi-
lar to many of the LigIV syndrome patients (4, 46). 
One of the effects of the Lig4Y288 mutation is a pro-
gressive attrition of hematopoietic stem cells in aged 
mice, although this is not limiting in young animals 
(27). Here, we provide a detailed characterization of 
the effects of the Lig4Y288 mutation on the immune 
system: describing a severe defect in lymphocyte 
development, a partial arrest in B cell class switching, 
and a defect in the survival of long-lived lymphocyte populations. 
Antibody responses to T cell–dependent and –independent anti-
gens are dramatically impaired. We also describe the unexpect-
edly high incidence of thymic malignancies in the Lig4Y288 mice 
and show that these can arise from aberrant resolution of V(D)J 
breaks leading to translocation of the T cell receptor locus. These 
findings provide important insights into the underlying basis of 
immune pathology of LigIV syndrome.
Results
Partial arrest in lymphocyte development in the Lig4Y288C strain. The 
Lig4Y288C mouse line was identified in an ENU mutagenesis program 
as a recessive C57BL/6 line with growth retardation and peripheral 
blood lymphopenia (27). The mice carry a Y288C substitution in 
the catalytic domain of LigIV, which reduces in vivo LigIV activ-
ity at least 10-fold and severely impairs the repair of DNA breaks 
Table 1
Reduced lymphocyte numbers in the blood and peripheral lymphoid organs of Lig4Y288C mice
Genotype	 	Total	nucleated	cells	(%)	 	 	 	 	Cell	count/105	per	mouse
	 	 Blood	 	 	 Spleen	 	 	Mesenteric	lymph	nodes	 Peritoneum
	 B	cell	 CD4+		 CD8+		 B	cell	 CD4+		 CD8+		 B	cell	 CD4+		 CD8+		 B2	cell	 B1	cell	
	 	 T	cell	 T	cell	 	 T	cell	 T	cell	 	 T	cell	 T	cell	
WT 31 ± 5 12 ± 2 5.0 ± 0.8 754 ± 148 251 ± 62 141 ± 42 114 ± 62 125 ± 40 80 ± 25 2.23 ± 1.7 2.35 ± 0.5
Lig4Y288C 2.9 ± 0.7 1.8 ± 0.3 1.5 ± 0.2 16 ± 11 10 ± 3 6 ± 2 3 ± 3 11 ± 7 4 ± 2 0.15 ± 0.1 0.38 ± 0.2
Numbers indicate means ± 95% CI; n ≥ 9. FACS plots representing B cell and CD4+ T cell populations in the blood previously published in ref. 27.
Figure 2
Impaired humoral immunity in Lig4Y288C mice. (A) Serum antibody isotype levels in 
naive WT and Lig4Y288C mice. Data points and bars represent the individual mice and 
the means of each dataset, respectively. (B) Antigen-specific antibody responses 
to T cell–independent (NP-Ficoll) and T cell–dependent (CGG) antigens in WT and 
Lig4Y288C mice (analyzed by ELISA, optical density plotted against the serum dilution 
factor). Error bars represent mean ± SEM. **P < 0.01.
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(27). The effects of the mutation at the molecular and cellular levels 
closely resemble those in human LigIV syndrome patients (4, 27).
We assessed the impact of the mutation on lymphocyte develop-
ment by comparing primary lymphoid organs of Lig4Y288C mice with 
those of age-matched WT and Rag1-null mice, all on a C57BL/6 
background. This revealed a severe but incomplete arrest in lym-
phocyte development in the Lig4Y288C strain (Figure 1). The total 
thymic cell count was 100-fold lower than in the WT and compa-
rable to that in the Rag1–/– mice. The loss of thymocytes increased 
progressively at each developmental transition, and the proportion 
of thymocytes at the CD25hiCD4–CD8– stage preceding the onset 
of TCRβ rearrangement was increased, consistent with impaired 
V(D)J recombination (Lig4Y288C = 48% ± 1% and WT = 26% ± 6% of 
double-negative thymocytes, mean and 95% CI; Figure 1, A and B).
The absolute numbers of pro–B (B220+CD43+), pre–B 
(B220+CD25+), and immature B cells (B220+IgM+IgD–) in the 
bone marrow of the Lig4Y288C mice also showed progressive cell 
loss, and a larger proportion of B220+ cells was arrested at the 
pro–B stage (Lig4Y288C = 33% ± 11% and WT = 13% ± 4% of B220+ 
bone marrow cells; Figure 1, C and D), consistent with impaired 
rearrangement of the IgH locus. Mature (B220+IgM+IgD+) B cells 
in the bone marrow could not be reliably detected but were found 
in low numbers in the periphery.
Lymphopenia and failure in antibody responses to challenge in the 
Lig4Y288C mice. The Lig4Y288C strain was originally identified based 
on the decreased frequency of recirculating lymphocytes (27), and 
the numbers of B and T cells in the blood of the Lig4Y288C mice 
were severely reduced (Table 1). Surprisingly, this was associated 
with elevated serum IgM (Figure 2A), which resembles some fea-
tures of hyper-IgM immunodeficiencies seen in other DNA repair 
syndromes, particularly those affecting B cell class switching (12). 
Elevated IgM levels were also reported in some patients with muta-
tions in LigIV and XLF (2, 8). Serum IgG3 levels in the Lig4Y288C 
mice were significantly reduced, whereas serum IgG1 and IgA were 
comparable to those in WT (Figure 2A).
The numbers of B and T cells in the secondary lymphoid organs, 
such as the spleen and mesenteric lymph nodes, were severely reduced 
(Table 1). CD4+ and CD8+ T cells were 10- to 25-fold down in num-
bers and stained positive for TCRαβ. Interestingly, most CD4+ T cells 
had an activated phenotype with increased expression of CD44 and 
reduced CD45RB (Supplemental Figure 1). Such T cell activation is 
frequently seen in other partial T cell immunodeficiency syndromes 
in humans and mouse models, for example, in the Omenn syndrome, 
in which a reduction in T cell numbers caused by hypomorphic muta-
tions in the RAG1/2 genes affects T cell tolerance and activation, prob-
ably by reducing competition for limiting amounts of prosurvival 
cytokines or costimulatory molecules (reviewed in refs. 47, 48).
The absolute numbers of B cells in the secondary lymphoid 
organs were reduced nearly 50-fold (Table 1), with a large relative 
increase in the proportion of transitional B cells (B220+CD23–
CD21–). The transitional B cell population constituted 86% ± 7% 
of B220+ splenocytes in the Lig4Y288C mice compared with only 32% 
Figure 3
Thymic tumors in Lig4Y288C mouse. (A) Fluorescence in situ hybridization analysis of a Lig4Y288C thymic tumor and normal thymus of a WT mouse: 
loss of pairing of the TCRα/δ flanking probes in cells of the Lig4Y288C thymic tumor (arrows) and in the inset section is indicative of chromosomal 
translocation at the locus. Scale bars: 5 μm. (B) Intact G2/M checkpoint in Lig4Y288C MEFs: WT (Atm+/+), ataxia telangiectasia–mutated (Atm–/–), 
and Lig4Y288C MEFs were irradiated with 0 to 5 Gy, and allowed to recover for 2 hours before analysis of mitotic index. Percentage of mitotic 
cells compared with nonirradiated cells is shown. Both Atm+/+ and Lig4Y288C cells display an intact G2/M arrest in contrast with Atm–/– MEFs, 
which continue to enter mitosis after irradiation. Error bars represent mean ± SD. (C) Lig4Y288C MEFs activate p53 normally: MEFs were either 
nonirradiated or irradiated with 10 Gy and allowed to recover for 4 hours before processing. Percentage of cells positive for phosphorylated p53 
was scored. Atm+/+ and Lig4Y288C MEFs have phosphorylated p53 after irradiation in contrast with Atm–/– MEFs. Error bars represent means + 
SD, from 3 independent experiments.
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Figure 4
Partial defect in immunoglobulin class switching in Lig4Y288C mice. (A) Anti-HEL antibody levels in the serum of WT-VHL (WT) and Lig4Y288C-VHL 
(Lig4Y288C) mice. Bars represent geometric means and 95% CI, n ≥ 3; comparisons by Mann-Whitney test, *P < 0.05. (B–D) Class switching 
of Lig4Y288C-VHL and control WT-VHL B cells at day 4 of in vitro stimulation with LPS, LPS plus IL-4, and anti-CD40 plus IL-4. (B) CFSE fluo-
rescence as a measure of the proliferation of Lig4Y288C-VHL (black lines) and WT-VHL (gray lines) CD19+ B cells, representative of 5 mice per 
group. (C) CD19+ versus IgG flow cytometry profiles of WT-VHL and Lig4Y288C-VHL splenocytes gated on the highly proliferated CFSE-low cells. 
Numbers indicate the percentages of class-switched B cells within each plot. (D) IgG+ cells as a percentage of the highly proliferated CFSE-low 
CD19+ B cells in Lig4Y288C-VHL, WT-VHL, Lig4+/Y288C-VHL (Lig4het), and Rag1–/–-VHL cultures at day 4 of in vitro stimulation. Error bars represent 
means ± 95% CI; n = 6 for WT and Lig4Y288C; n = 3 for Lig4het and Rag1–/–. **P < 0.01; ***P < 0.001 using ANOVA.
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± 14% in the WT (data not shown). This suggested that further 
loss of B cells may have been occurring in the peripheral lymphoid 
organs after the cells progressed from the transitional to the 
mature stage, as demonstrated later in this study.
In the peritoneal cavity, despite a large reduction in conventional 
IgMloB220hi B2 cells, a considerable population of IgMhiB220lo B1 
cells was retained (Table 1 and Supplemental Figure 2A). These cells 
had the typical phenotype of B1 cells — high forward scatter, low 
expression of IgD, higher expression of CD9, MAC1, and CD43 — 
and were also CD5+ (Supplemental Figure 2B). In scidDNA–PKcs mice, 
B1 cells were previously associated with serum autoantibodies (49), 
and autoantibodies and autoimmune thrombocytopenia were also 
reported in some LigIV patients (8). Thus, we analyzed Lig4Y288C for 
serum autoantibodies. We observed some increase in the incidence 
of IgM autoantibodies largely targeting cytosolic proteins; however, 
no IgG autoantibodies were found (Supplemental Figure 2C).
To further characterize the immunodeficiency in the Lig4Y288C 
strain, we assessed humoral responses to challenge with T cell–
dependent (chicken γ globulin [CGG]) and T cell–independent 
(4-hydroxy-3-nitrophenylacetyl aminoethylcarboxymethyl–Ficoll 
[NP-Ficoll]) antigens. We observed an almost complete loss of 
antibody responses in Lig4Y288C mice (Figure 2B), consistent with 
the reported failure of several LigIV patients to mount antibody 
responses to immunization or infection (8). This highlights the 
dramatic impairment in humoral immunity in the LigIV syn-
drome, which likely arises from severe lymphopenia together with 
additional defects in Ig class switching, cell proliferation, and sur-
vival, as reported later in this study.
Increased incidence of thymic tumors in the Lig4Y288C mice. The Lig4Y288C 
mice showed high incidence of lymphoid malignancies. Malignan-
cies were found in 12 out of 45 Lig4Y288C mice analyzed, compared 
with none of the WT or Lig4Y288C/+ littermates. In 8 of 12 of the affect-
ed animals, the malignancies were of thymic origin and CD4+CD8+ 
cell surface profile, and in 1 mouse, the malignant cells were of 
B220loIgMhi B1 cell phenotype and spread in the peritoneum and 
spleen. Some of the affected mice were as young as 6 weeks.
To analyze the mechanisms that lead to carcinogenesis, we studied 
1 of the thymic tumors for chromosomal translocations involving 
TCR loci by looking for evidence of separation of red and green FISH 
probe pairs derived from BACs flanking the TCRα/δ, -β, and -γ loci. 
In this way, we found chromosomal separation of 54% (216/398) of 
TCRα/δ probes in the tumor cells, indicative of a translocation (Fig-
ure 3A). This observation suggests that thymic tumors in the LigIV 
syndrome can arise from aberrant resolution of DNA breaks at the 
TCR locus, probably during V(D)J recombination.
The high incidence and early age of onset of tumors in Lig4Y288C 
mice was unexpected. In other NHEJ-deficient mouse strains, a 
high incidence of cancer typically results from a combined defect 
in DNA repair and cell-cycle checkpoints, such as in the NHEJ-defi-
cient p53–/– mouse strains (43–45). Thus, we analyzed the effects of 
the Lig4Y288C mutation on G2/M cell cycle checkpoint arrest and on 
p53 phosphorylation in mouse embryonic fibroblasts (MEFs). The 
data show that Lig4Y288C MEFs undergo normal G2/M cell-cycle 
arrest and phosphorylate p53 normally following irradiation (Fig-
ure 3, B and C), which is consistent with previous findings from 
Lig4–/– MEFs and the cells of LigIV syndrome patients (4, 13).
The role of LigIV in B cell receptor class switching. To assess the impact 
of the Lig4Y288C mutation on B cell class switching, we crossed the 
following B cell receptor transgenes onto the Lig4Y288C line to gener-
ate Lig4Y288C-VHL (where VHL indicates variable heavy light) mice: an 
anti–hen egg lysozyme (anti-HEL) κ light chain transgene and an 
“IgH knockin” that is capable of switching. To increase litter sizes, 
the cross was on a mixed C57BL/6×NOD background and age-
matched littermates were used as controls in all the comparisons 
to minimize any differences in genetic background between the 
groups. In VHL mice, the vast majority of B cells showed specificity 
for HEL, and the VHL transgene resulted in a partial rescue of B cell 
development and peripheral B cell numbers in the Lig4Y288C-VHL 
mice. Thus, the average number of HEL-binding B cells in the spleen 
of the Lig4Y288C-VHL mice was 3.3 × 106, compared with 0.7 × 106 B 
cells in the nontransgenic Lig4Y288C and 23 × 106 B cells in the WT-
VHL controls. We also measured serum anti-HEL antibody levels 
in the Lig4Y288C-VHL mice: IgG1, IgG2a, and IgG2b levels were signifi-
cantly reduced relative to WT-VHL (P < 0.05), but IgM, IgG3, and 
IgA titers were within normal range (Figure 4A).
We chose to assess Ig class switching in an in vitro system, using 
the previously described protocols that provide a control for reduced 
B cell number, reduced provision of T cell help, and any changes in B 
cell proliferation (33, 36, 50, 51). Specifically, cell proliferation in the 
Lig4Y288C strain was assessed and controlled for using CFSE labeling. 
Figure 5
Impaired peripheral lymphocyte survival contributes to immunodefi-
ciency in Lig4Y288C mice. (A) Flow cytometry profiles of the spleen of 
Lig4+/+IgHELRag1–/– and Lig4Y288CIgHELRag1–/– mice stained for B220, 
CD21, and CD23 and gated on B220+ cells. Numbers indicate the per-
centages of splenic B cells within the transitional CD21–CD23–, follicu-
lar CD21+CD23+, and marginal zone CD21hiCD23lo gates. (B) Absolute 
number of B cells in the bone marrow, mesenteric lymph nodes (MLN), 
and spleen of Lig4+/+IgHELRag1–/– (WT) and Lig4Y288CIgHELRag1–/– 
(Lig4Y288C) mice. Data points and bars represent individual mice and 
the mean of each dataset, respectively. Bone marrow immature B cells 
were gated as B220+IgM+HSAhi and mature B cells as B220+IgM+HSAlo; 
splenic transitional B cells were gated as B220+CD21–CD23–, follicular 
as B220+CD21+CD23+, and marginal zone as B220+CD21hiCD23lo; B 
cells in the MLN were gated as B220+IgM+IgD+. *P < 0.05, 2-tailed 
Student’s t test.
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CFSE-loaded Lig4Y288C-VHL and WT-VHL splenocytes were cultured 
for 4 days with LPS, LPS plus IL-4, or anti-CD40 plus IL-4. The 
Lig4Y288C-VHL B cells showed impaired proliferation in response to 
LPS and LPS plus IL-4 stimulation, but surprisingly, proliferation in 
response to anti-CD40 plus IL-4 stimulation was normal (Figure 4B). 
To control for differences in cell proliferation, highly proliferated 
CFSElo cells were gated, and the proportions of switched IgG+ B cells 
was measured. Lig4Y288C-VHL B cells showed significantly less switch-
ing to IgG1 and IgG3 with all 3 classes of stimuli (Figure 4, C and D). 
Thus, switching to IgG1 in response to LPS plus IL-4 was reduced 
from 10% ± 5% in WT-VHL to 1.4% ± 1.5% in Lig4Y288C-VHL, and 
switching to IgG3 in response to LPS was reduced from 3.5% ± 1.9% 
to 0.7% ± 0.5% (P < 0.001 and P < 0.01, respectively). Importantly, 
switching in cultures stimulated with anti-CD40 plus IL-4, where 
there was no difference in cell proliferation, was also significantly 
reduced, from 25% ± 10% to 10% ± 5% (P < 0.01), confirming that the 
impaired switching is not a side effect of low proliferation.
To account for the differences in T cell numbers in the cultures 
and for possible differences in B cell repertoire that could arise 
through B cell receptor editing, we used Rag1-VHL (VHL-knockin, 
Rag1–/–, Lig4+/+) controls. Using ANOVA, we found no difference 
in switching between WT-VHL and Rag1-VHL cultures, suggesting 
that the above factors have no effect, whereas Lig4Y288C-VHL switch-
ing was reduced relative to both control groups (Figure 4D).
Impaired peripheral lymphocyte survival contributes to immunodeficiency. 
To assess the impact of the impaired repair of background DNA 
damage on lymphocyte survival, we created a system in which the 
Lig4Y288C B cells could develop without undergoing V(D)J rear-
rangement or Ig class switching. To achieve this, we crossed the 
MD4 IgHEL transgene and the Rag1-null allele onto the Lig4Y288C 
strain to generate Lig4Y288CIgHELRag1–/– mice. These mice were com-
pared with age-matched Lig4+/+IgHELRag1–/– littermates, all on an 
inbred C57BL/6 background. In these mice, the rearrangement of 
the endogenous immunoglobulin loci is prevented by the lack of 
RAG-1, and all B cells express the transgenic MD4 B cell recep-
tor, which does not undergo class switching. Furthermore, both 
groups of mice lack T cells, controlling for indirect effects of T 
lymphocytes on B cell turnover.
Analysis of the mice showed no differences in the numbers of 
immature (B220+IgM+HSAhi) B cells in the bone marrow or tran-
sitional (B220+CD21–CD23–) B cells in the spleen between the 
Lig4Y288C and Lig4+/+ groups (Figure 5, A and B), which demonstrates 
that the impaired B cell development in the Lig4Y288C mutant is 
entirely limited by a defect in V(D)J rearrangement. However, the 
numbers of long-lived B cell populations, such as the follicular 
(B220+CD21+ CD23+) and marginal zone (B220+CD21hi CD23lo) 
B cells in the spleen and mature B cells in the mesenteric lymph 
nodes (B220+IgM+IgD+), were reduced in the Lig4Y288CIgHELRag1–/– 
mice compared with the Lig4+/+IgHELRag1–/– controls (Figure 5B). 
The number of mature (B220+IgM+HSAlo) B cells in the bone 
marrow was also lower in the mutants, though the difference 
did not reach statistical significance (Figure 5B). This indicates 
a biologically important function of NHEJ in the maintenance of 
genomic stability in peripheral lymphocytes, independent of its 
roles in V(D)J rearrangement and class switching, and suggests 
that impaired peripheral lymphocyte survival contributes to the 
immunodeficiency in the LigIV syndrome.
Increased turnover of lymphocytes in the secondary lymphoid 
organs of the Lig4Y288 mice was confirmed by a BrdU-incorpora-
tion assay. Nontransgenic WT and Lig4Y288 mice were fed BrdU at 
0.25 mg/ml in drinking water for 1 week, and after this period, 
66% ± 23% of B cells and 62% ± 5% of T cells in the spleen of the 
Lig4Y288C mice stained BrdU+ compared with only 31% ± 6% of B 
cells and 19% ± 5% of T cells in the WT group; and a similar differ-
ence was seen in the mesenteric lymph nodes.
Discussion
The hypomorphic mouse strain Lig4Y288C generated in an ENU 
mutagenesis program is, we believe, the first viable animal model 
of the LigIV syndrome. Like LigIV syndrome patients, the Lig4Y288C 
mice show an over 10-fold reduction in LigIV activity and similar 
general phenotypic features of growth retardation and lympho-
penia. In this study, we provide a detailed analysis of the effects 
of the hypomorphic LigIV deficiency on the mammalian immune 
system. This demonstrates how the generation of point mutations 
by ENU mutagenesis mimics naturally occurring hypomorphic 
mutations and allows an investigation of gene functions that are 
masked by embryonic lethality in gene-knockout lines.
We report profound immunodeficiency in Lig4Y288C mice, with 
primary and secondary lymphoid organ lymphopenia. Surpris-
ingly, IgG1 and IgA (but not IgG3) antibody isotypes in Lig4Y288C 
serum are maintained at normal levels, despite the very low num-
bers of peripheral B cells and impaired Ig class switching, which 
suggest that compensatory mechanisms must be present. These 
might operate at the level of B cell selection, T cell activation, 
competition for other B cell and plasma cell survival factors, or 
antibody clearance. When immunized, the Lig4Y288C mice show an 
almost complete loss of antigen-specific antibody responses to T 
cell–dependent and T cell–independent antigens. This resembles 
features of the human LigIV syndrome (6, 8) and highlights the 
dramatic loss of immune system function caused by the LigIV 
mutations. We further demonstrate that, in addition to the well-
characterized arrest in V(D)J rearrangement, impaired survival of 
long-lived lymphocyte populations also contributes to immuno-
deficiency. By creating a system in which Lig4Y288C B cells develop 
without undergoing V(D)J rearrangement or class switching and 
controlling for T cell numbers, we demonstrate the impact of 
background DNA damage on these long-lived lymphocyte popu-
lations and the role of NHEJ in their maintenance. We also report 
overall activation of peripheral T cells, retention of B1 cells, and 
some increase in IgM autoantibodies in the Lig4Y288C mice. These 
phenotypes have not been previously assessed in any of the LigIV 
syndrome patients; however, autoimmune thrombocytopenia 
was seen in at least 1 patient and also in patients with muta-
tions in XLF (2, 8), suggesting that IgM autoantibodies may be 
relevant in NHEJ deficiency syndromes.
We show impaired class switching in Lig4Y288C B cells, demon-
strating the involvement of LigIV and the NHEJ pathway in the 
class switching reaction. This confirms the recent conclusions of 
Yan et al. from studies of Lig4–/–p53–/– B cells (35), in this case using 
LigIV-deficient B cells without additional defects in DNA dam-
age response pathways. Our experimental system directly assesses 
switching at the cellular level and shows that Lig4Y288C B cells are 
defective in class switching to 2 different antibody isotypes with 3 
different stimuli, and this is independent of differences in B cell 
proliferation, B cell receptor specificity, or T cell help. Some switch-
ing in Lig4Y288C is probably due to the residual activity of LigIV, 
with possible contributions of alternative repair pathways (35, 39). 
However, despite the contribution of alternative repair pathways 
to class switching (35, 39), our findings show that hypomorphic 
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mutations in LigIV can significantly impair B cell class switching 
and contribute to the immunodeficiency of LigIV syndrome.
We further report an unexpectedly high incidence of CD4+CD8+ 
thymic tumors in Lig4Y288C mice, suggesting that LigIV deficiency 
predisposes to malignancies. The Lig4Y288C tumors are associated 
with chromosomal translocations at the TCRα/δ locus, prob-
ably caused by aberrant repair of RAG-induced DNA breaks. The 
strong predisposition to cancer in Lig4Y288C mice suggests that the 
mutations that similarly impair LigIV activity in humans will also 
predispose to cancer and that T cell leukemias reported in some 
LigIV syndrome patients may arise through similar mechanisms 
(5, 11). This conclusion is of clinical interest, as the DNA repair 
deficiency is associated with adverse response to radio- and che-
motherapy in this group of cancer patients (5, 11). It also further 
highlights the possibility that small alterations in LigIV activity 
in heterozygous carriers of Lig4 mutations may predispose to can-
cer, as suggested by the fact that Lig4 haploinsufficiency increases 
the frequency of soft-tissue sarcomas in INK4a/ARF-null mice 
(52) and by the association of a human LIG4 polymorphism with 
increased risk of lung carcinomas (53).
The high cancer susceptibility of the Lig4Y288C line compared 
with other NHEJ-deficient mouse strains is surprising, as it is 
widely believed that defects in NHEJ repair lead to carcinogen-
esis only when combined with loss of cell-cycle checkpoints, as in 
the NHEJ-deficient p53–/– strains (42–45). Although Ku70–/– mice 
were reported to develop CD4+CD8+ lymphomas similar to those 
of Lig4Y288C mice (54), this was disputed in recent reports argu-
ing that both Ku70–/– and Ku80–/– strains are not tumor prone 
(40, 55). Furthermore, Lig4–/–p53R172P/R172P mice with a defect in 
DNA damage apoptosis induction but normal cell-cycle arrest 
are tumor free (56). In contrast, we observed high rates of leuke-
mia in Lig4Y288C mice despite normal G2/M checkpoint arrest and 
normal p53 activation, and the reason for increased cancer pre-
disposition in Lig4Y288C compared with other NHEJ-null mouse 
strains is unknown. We can speculate that because the tumors 
arise from the CD4+CD8+ population, progression of some thy-
mocytes to the CD4+CD8+ stage may be a prerequisite for carci-
nogenesis. Thus, the increased incidence of malignancies in the 
Lig4Y288C mice may be the result of the hypomorphic nature of 
the phenotype that allows some “leaky” T cell development to 
take place, as is also seen in the tumor-prone and “leaky” Ku70–/– 
line (54). It is also possible to speculate that the accessibility of 
DNA breaks to alternative error-prone repair pathways may dif-
fer between the different NHEJ-deficient mouse lines, leading to 
increased predisposition to aberrant repair and translocations 
in some of the lines, such as Lig4Y288C. Although many questions 
remain unanswered, our findings with Lig4Y288C mice provide 
definitive evidence that hypomorphic LigIV deficiencies can pre-
dispose to leukemia.
In summary, access to the ENU-induced hypomorphic Lig4Y288C 
mouse strain has made it possible to characterize the effects of 
LigIV deficiency on the mammalian immune system. Arrest in 
V(D)J rearrangement is the primary cause of lymphopenia, with 
impaired cell survival and proliferation due to random DNA dam-
age making additional contributions to the loss of peripheral 
lymphocytes. We confirm the role of LigIV in normal B cell class 
switching and suggest that class switching deficiencies contrib-
ute to the impaired immune function in LigIV syndrome. We also 
show that a hypomorphic LigIV mutation can confer strong pre-
disposition to lymphoid malignancies. The study reveals multiple 
NHEJ-dependent processes in immune system function and helps 
to explain the complex and multilayered immunodeficiency of the 
human LigIV syndrome.
Methods
Mouse strains. The Lig4Y288C mouse strain carries a hypomorphic Y288C 
mutation in the Lig4 gene on the C57BL/6J strain background (27). The 
C57BL/6 MD4 strain carries an anti-HEL immunoglobulin transgene 
(IgHEL) encoding the heavy and light chains of IgMa and IgDa antibody 
isotypes, originally derived from the HyHEL10 hybridoma (57). The VHL 
strain has the same HyHEL10 antibody specificity, comprising an anti-
HEL κ light chain transgene and a VDJ segment targeted to the heavy-
chain locus and expressed with endogenous constant region exons (both 
gifts from Jason Cyster, UCSF, San Francisco, California, USA). C57BL/6 
Rag1-null mice were previously described (58). All mice were fewer than 
14 weeks old and were maintained under specific pathogen–free con-
ditions. All the experiments were approved by the Australian National 
University Animal Ethics and Experimentation Committee and the 
Oxford University Ethical Review Committee and were conducted under 
a United Kingdom Home Office license.
Flow cytometry. FITC-conjugated antibodies were against the following: 
CD21/CD35 (7G6), CD24 (HSA, M1/69), IgDa (AMS9.1), IgMb (AF6-
72) (BD Biosciences — Pharmingen); and B220, CD8α, CD11b (MAC1, 
M1/70.15), and CD44 (CALTAG; Invitrogen). PE-conjugated antibodies 
were against the following: CD23 (FcεRII, B3B4), CD43 (Ly-48, S7), CD5 
(Ly-1, 53-7.3), IgMa (DS-1), IgDb (217-170) (BD Biosciences — Pharmin-
gen); and CD25 (PC61-5.3) and CD4 (CALTAG; Invitrogen). APC-conju-
gated antibodies were against the following: IgM (II/41) (BD Biosciences 
— Pharmingen) and B220 (RA3-6B2) and CD4 (CALTAG; Invitrogen). Tri-
color-conjugated (TC-conjugated) anti-CD8α (16A) (CALTAG; Invitrogen) 
and biotin-conjugated anti-CD9 (KMC8) (BD Biosciences — Pharmingen) 
followed by streptavidin-TC (CALTAG; Invitrogen) were also used. The 
data were collected on FACSCalibur or FACSCanto (BD).
Mouse immunizations. Mice were immunized intraperitoneally with 50 μg 
of alum-precipitated CGG (Jackson ImmunoResearch Laboratories Inc.) 
or 25 μg NP–Ficoll (4-hydroxy-3-nitrophenylacetyl aminoethylcarboxy-
methyl–Ficoll; Biosearch Technologies) and bled from the tail vein on days 
14 or 6 after immunization, respectively. Four weeks after the first immu-
nization, mice were boosted with a secondary immunization of CGG and 
serum collected after 7 days.
Measurement of serum antibody titers. Serum antibody titers were mea-
sured by ELISA in 96-well plates (Greiner Bio-One) coated with 10 μg/ml 
HEL (Sigma-Aldrich), 5 μg/ml CGG, 20 μg/ml NP-BSA (Biosearch Tech-
nologies), or 2 μg/ml of antibodies for mouse IgM (II/41), IgA (C10-3), 
IgG1 (A85-3), IgG2a (RII-89), or IgG3 (R2-38) (all from BD Biosciences 
— Pharmingen) in carbonate buffer, pH 9.8. The plates were blocked with 
1% BSA (Sigma-Aldrich) in PBS. Detection antibodies used were the bioti-
nylated anti-mouse IgMa (DS-1), IgA (C10-1), IgG1 (A85-1), IgG2a/b (R2-40), 
and IgG3 (R40-82) (all from BD Biosciences — Pharmingen) followed by an 
avidin-alkaline phosphatase (AP) conjugate (Sigma-Aldrich). Alternatively, 
AP-conjugated goat anti-mouse polyclonal antibodies for IgM (Sigma-
Aldrich), IgA, IgG1, IgG2a, and IgG3 (SouthernBiotech) were used. Plates 
were washed in PBS with 0.05% Tween-20, developed with 1 mg/ml Sigma-
Aldrich 104 phosphatase substrate, and read at 405 nm with a Bio-Rad 550 
plate reader. Serum antibody concentration was determined by compari-
son with either a serum standard of known concentration or appropriate 
purified mouse isotype controls (BD Biosciences — Pharmingen).
Fluorescence in situ hybridization. BAC probes (>100 kb in length) flank-
ing the TCRα/δ (RP24-336119 and RP23-9-18), TCRβ (RP24-164B11 and 
RP23-97020), and TCRγ loci (RP23-97G21 and RP24-34719) were obtained 
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from BACPAC Resource Center and DNA prepared with QIAGEN Midi 
kits. FISH probes were labeled with spectrum orange or spectrum green 
dyes (Abbott Diagnostics) using the BioPrime Kit (Invitrogen). After clean-
ing with a ChargeSwitch kit (Invitrogen), the probes were resuspended in 
hybridization mix (Abbott Diagnostics) and hybridized to 7-μm tissue sec-
tions. Images were taken with a Zeiss Axioskop fluorescence microscope. 
Sections were scored for total, paired, and unpaired probes (in normal sec-
tions greater than 90% red and green probes were closely linked).
Class switching assays. In vitro assays to assess class switching while con-
trolling for differences in cell proliferation were performed as previously 
described (33, 36, 50). Splenocytes from VHL transgenic WT and Lig4Y288C 
littermates on a mixed C57BL/6×NOD background were labeled with CFSE 
using Vybrant Kit (Molecular Probes; Invitrogen). In brief, the cells were 
incubated at 2 × 107 cells/ml in 5 μM CFSE in PBS for 10 minutes at 37°C 
and washed 3 times in RPMI 1640 (Sigma-Aldrich). The cells were then 
cultured at 6.5 × 105 cells/ml in RPMI 1640 supplemented with 10% FCS 
(First Link [UK] Ltd.), 2 mM l-glutamine (Sigma-Aldrich), 10 mM HEPES, 
pH 7.4 (Gibco; Invitrogen), 100 μg/ml streptomycin, 100 U/ml penicillin 
(Sigma-Aldrich), and 50 μM β-mercaptoethanol (Gibco; Invitrogen) at 
37°C and 5% CO2. Some of the cultures were stimulated with 5 μg/ml of 
LPS (Sigma-Aldrich), or 5 μg/ml anti-mouse CD40 antibody (HM40-3; BD 
Biosciences — Pharmingen), with or without 5 ng/ml IL-4 (Sigma-Aldrich). 
At day 4, the cells were collected and stained with a biotin-conjugated anti-
mouse CD19 antibody (1D3; BD Biosciences — Pharmingen) followed by 
polyclonal PE-conjugated goat anti-mouse IgG1, IgG2a, IgG2b, IgG3 (South-
ernBiotech), and streptavidin-TC (CALTAG; Invitrogen).
Checkpoint assays. p53 activation was used to assess G1/S checkpoint 
arrest, and changes in mitotic index after irradiation were used to moni-
tor G2/M progression. For p53 analysis, primary MEFs were grown to 
confluency on glass cover slips, irradiated with 10 Gy, rested for 4 hours, 
fixed in 3% paraformaldehyde with 2% sucrose in PBS for 10 minutes, per-
meabilized with 0.2% Triton X-100 in PBS for 2.5 minutes, and washed in 
PBS. Cells were stained with anti–phospho-p53 antibody (Cell Signaling 
Technology) at 1:100 in PBS with 2% BSA for 30 minutes at 37°C. Follow-
ing PBS washing, secondary antibody incubation was with Cy3 anti-rab-
bit IgG at 1:200 (Sigma-Aldrich). For G2/M analysis, transformed MEFs 
were grown on glass cover slips to approximately 60% confluency, irradi-
ated with 1–5 Gy, rested for 2 hours, and fixed, permeabilized, and washed 
as above. All samples were stained with 4′-6-diamidino-2-phenylindole 
(Sigma-Aldrich) for 10 minutes at room temperature to reveal the nuclei. 
Cover slips were mounted in VECTASHIELD (Vector Laboratories) and 
cells scored under fluorescence microscope using ×100 objective, counting 
approximately 200–500 cells per sample.
BrdU incorporation. BrdU (Sigma-Aldrich) was supplied at 0.25 mg/ml in 
drinking water supplemented with 1% glucose (Sigma-Aldrich) for 1 week. 
Cells were fixed in 0.5% paraformaldehyde in PBS and permeabilized in 
fresh 3 M HCl with 0.5% Tween-20, both incubations for 20 minutes at 
room temperature. The acid was neutralized with 0.1 M borax (Sigma-
Aldrich) and the cells washed and stained with FITC-conjugated anti-BrdU 
antibody (3D4, BD Biosciences — Pharmingen).
Screen of mouse serum for autoantibodies. Screen for autoantibodies was per-
formed using HEp-2000 ANA-Ro Test System slides (ImmunoConcepts; 
Alpha Laboratories) according to the manufacturer’s protocol.
Statistics. Statistical comparisons were performed with Prism 4.0 soft-
ware (GraphPad Software) using 2-tailed Student’s t test for compari-
sons of 2 data sets and ANOVA for multiple comparisons. P ≤ 0.05 was 
considered significant.
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